Trial
NCT04697485
Polydiuretic Therapy for Heart Failure With Preserved Ejection Fraction and Diabetes Mellitus
Phase IVWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Northwestern University
Collaborators
—
Condition
HF - Heart Failure
Intervention
Bumetanide 0.5 mg, dapaglifozin 5 mg, eplerenone 25 mg
Why stopped
Enrollment and funding challenges
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-05-10